STE logo

STERIS plc Stock Price

NYSE:STE Community·US$20.5b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 14 Fair Values set on narratives written by author

STE Share Price Performance

US$212.30
-25.95 (-10.89%)
US$256.86
Fair Value
US$212.30
-25.95 (-10.89%)
17.3% undervalued intrinsic discount
US$256.86
Fair Value
Price US$212.30
AnalystConsensusTarget US$256.86

STE Community Narratives

·
Fair Value US$256.86 17.3% undervalued intrinsic discount

Healthcare Demand And Facility Expansion Will Create Value

0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
US$256.86
17.3% undervalued intrinsic discount
Revenue
6.6% p.a.
Profit Margin
14.84%
Future PE
28.22x
Price in 2029
US$317.03

Trending Discussion

Updated Narratives

STE logo

STE: Share Repurchases And Recurring Platform Earnings Will Support Future Upside

Fair Value: US$256.86 17.3% undervalued intrinsic discount
7 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Solid track record with excellent balance sheet and pays a dividend.

1 Risk
4 Rewards

STERIS plc Key Details

US$5.9b

Revenue

US$3.3b

Cost of Revenue

US$2.6b

Gross Profit

US$1.8b

Other Expenses

US$782.3m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
8.03
44.24%
13.18%
26.8%
View Full Analysis

About STE

Founded
1985
Employees
17937
CEO
Daniel Carestio
WebsiteView website
www.steris.com

STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. It operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The company offers cleaning chemistries and sterility assurance products, automated endoscope reprocessing system and tracking products, endoscopy accessories, instruments, washers, and sterilizers and other pieces of capital equipment, as well as equipment used directly in the procedure rooms, including surgical tables, lights, equipment management services, and connectivity solutions; and various preventive maintenance programs, repair services, custom process improvement consulting, and outsourced instrument sterile processing, as well as instrument, devices, and endoscope repair and maintenance services. It also provides process controls and monitoring systems, as well as integrated sterilization equipment, such as accelerators, product handling, and automation; and sterilization modalities, product development, materials testing, and process validation, as well as support services for sterilization equipment and control systems comprising installation, preventive maintenance, updates, repairs, and troubleshooting. In addition, the company offers pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators; and preventive maintenance programs and repair services to support the operation of capital equipment. It serves healthcare providers, medical device and pharmaceutical manufacturers, biopharmaceutical manufacturing facilities, and hospitals. The company was formerly known as New STERIS Limited and changed its name to STERIS plc in November 2015. STERIS plc was founded in 1985 and is headquartered in Mentor, Ohio.

Recent STE News & Updates

Narrative Update Jun 24

STE: Share Repurchases And Recurring Platform Earnings Will Support Future Upside

Analysts have made a small adjustment to their price target on STERIS, keeping fair value around $256.86 while fine-tuning assumptions on discount rate, revenue growth, profit margin and future P/E to reflect updated expectations for the business. What's in the News STERIS reported fiscal 2026 adjusted EPS of $10.17 compared with $9.22 a year earlier and total revenue of $5.94b, with broad-based revenue growth led by healthcare and faster percentage gains in Life Sciences.

Recent updates

No updates